TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer comments on Johnson & Johnson's (JNJ) move to abandon merger talks with Actelion. "One of the reasons [Johnson & Johnson] has that great balance sheet is because they don't overpay," Cramer said. The cause for the failed talks was pricing, according to the Wall Street Journal and the deal may have been worth upwards of $30 billion. Reports suggest Sanofi (SNY) is in merger talks with Actelion. Cramer spoke earlier from the floor of the New York Stock Exchange.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.